The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.

The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer ...

Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...

Class action and personal injury lawsuits have been filed in US courts after the Food and Drug Administration warned in 2019 that some ranitidine drugs including Zantac contained low levels of an ...

These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent ...

GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company.

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer has agreed to settle most of the Zantac cases against it in state court ...